TEM snapshot historyBase and published updates, newest first.
EventPriceVS BASEVS PRIORVol. ratioRSI52w pos.EMA trend
Aftermarket · S11 · 18:02$64.62-4.80%+0.27%––––
S11 · 16:02$64.44-5.07%-0.02%––––
S11 · 10:53$64.45-5.05%-0.22%––––
S10 · 16:05$64.60-4.83%+3.20%––––
S10 · 10:54$62.43-8.03%+0.72%––––
S9 · 18:00$61.94-8.75%-3.37%––––
S9 · 12:08$64.23-5.38%+2.88%––––
Base · 14:14$67.880.00%0.00%1.83x80.7364.45%56.01 > 52.93 > 51.57
Try of the DayFinally

Committee read

  • Support — company-specific catalyst with 9.49% return and 4.74x time-relative volume
  • Counter-case — the move is extended
  • Unresolved — next-session follow-through.
Price record

Observed price path

Base price $67.88 · Updated with each published update.
TEM observed price path
Structural context

Price channel and relative performance

Six-month price channel · 20-session excess versus sector.
TEM six-month price channel and 20-session relative performance versus sector

Public scanner fields captured at the base snapshot; deeper research inputs remain private.

Snapshot

What was captured at the base

Base price$67.88
Change on day+10.82%
Volume vs 3-month average1.83x 3-month average
RSI (14)80.73

Structure

How price is behaving

Price vs session VWAPAbove VWAP · $66.57 · +1.97% from VWAP
EMA trend56.01 > 52.93 > 51.57
52-week position64.45% of 52-week high
ATR extension from EMA21Healthy · 3.58 ATR from EMA21
Session range position74% of session range

Risk and context

What may change the read

Relative strengthIdiosyncratic · +11.53% vs QQQ
Volume percentile95.20th percentile · Exceptional
Gap at open0.00%
Earnings riskClear
Short interest33.27%
Days to cover6.25
CatalystDeere, Coinbase Global, Nordson And Other Big Stocks Moving Higher On Wednesday

Base framework for context and outcome tracking. These are not trading instructions.

Base$67.88
Downside$61.61
Upside 1$74.15
Upside 2$80.42

Tracking results

+1 sessions
Observed price$72.69CoverageComplete+7.47% from $67.88 baseAug 21, 2026 · 17:05 NASDAQGSAdvance +7.87% · Drawdown -3.53%
+5 sessions
Observed price$70.69CoverageComplete+4.51% from $67.88 baseAug 27, 2026 · 17:05 NASDAQGSAdvance +7.87% · Drawdown -5.96%
+10 sessions
Observed price$64.66CoverageComplete-4.41% from $67.88 baseSep 3, 2026 · 17:05 NASDAQGSAdvance +7.87% · Drawdown -11.21%
+15 sessions
Observed price$59.01CoverageComplete-12.76% from $67.88 baseSep 11, 2026 · 17:05 NASDAQGSAdvance +7.87% · Drawdown -14.22%

Observed daily-bar ranges are retrospective measurements, not targets, stops, or trading instructions.

Five analytical lenses

Tryding Review

Adversarial review

Five AI analytical agents reading the same evidence; disagreement stays visible.

Elena Vartanyanindependent statistical auditor
“TEM has a 9.49% move and 4.74x time-relative volume. That is attention, not proof.”

The falsifier is loss of VWAP with fading participation.

Marcus Feldinformation, fundamentals and catalyst analyst
“The clinical result and Personalis acquisition create a candidate-specific mechanism.”

ANDG is credible, but TEM better explains why today.

Context roundtable

Broader Market Context

No public context roundtable was captured for this publication.

Coffee conversation

No coffee conversation was captured for this publication.

Follow-up

Timeline

Session 15 · Sep 11, 2026 · 18:17 NASDAQGS
Terminal closure💬$59.16-12.85% base+0.61% prior

TEM's 15-session tracking closes at -12.76% from the $67.88 reference. The path reached +7.87% at best and -14.22% at worst. Fresh closure evidence records a $59.01 provider price (-13.07% versus the reference) and a $59.05 post-market quote (+0.07% versus the regular close). Current session-average price, RSI, EMA trend and 52-week position readings are unavailable; traded volume is 0.57 times average. The confirmed Tempus issuer release remains company context, not proof it caused or sustained the return. The continuation condition failed, so public tracking ends.

Session 14 · Sep 10, 2026 · 10:34 NASDAQGS
Relevant update💬$60.21-11.30% base-1.58% prior

TEM's tracked loss widened 1.87 points to -11.27% since the last public note. The latest capture slipped 1.75% to .21, although price sat 1.61% above VWAP near the top of its range; participation was only 0.24 times average and decelerating, with no confirmed structure. Older Healthcare-relative strength keeps the event case relevant, but the stated continuation condition remains unproven.

Session 13 · Sep 9, 2026 · 10:33 NASDAQGS
💬$62.57-7.82% base-2.53% prior

TEM's tracked loss widened 3.03 points to -7.98% as the latest capture fell 2.68% to USD 62.57, 0.89% below VWAP on just 0.22x average volume, with no confirmed structure. The event-linked case remains relevant because TEM is still up 12.37% over 20 sessions while Healthcare is down 0.85%, but that older relative strength cannot repair the failed short-term hold; the continuation thesis remains unconfirmed.

Session 10 · Sep 3, 2026 · 16:05 NASDAQGS
💬$64.60-4.83% base+3.20% prior

TEM's tracked loss narrowed 2.06 points to -5.13% as the latest capture rose 4.29% to $64.60 and moved 2.3% above VWAP near the top of its range. That is a meaningful price repair, but only 0.59 times average volume and no confirmed structure leave the event-driven continuation thesis conditional: the tape has recovered part of the move, not yet demonstrated durable demand.

Session 9 · Sep 2, 2026 · 18:00 NASDAQGS
💬$61.94-8.75% base-3.37% prior

TEM's tracked result fell 2.57 points to -8.43% after the latest capture slipped 0.53% to $61.94. The event-driven case remains a plausible explanation, and long-window Healthcare-relative strength still supports attention, but price is 2.01% below VWAP in the lower part of its range on 0.87 times average volume with no confirmed structure; the continuation condition has failed again.

Session 6 · Aug 29, 2026 · 01:41 NASDAQGS
💬$64.04-5.66% base-6.53% prior

TEM tracked result fell 6.36 points to -5.32% as the current capture dropped 9.41% to 64.04 on 1.31x average volume, with no fresh VWAP reading. The 20-session return remains strong at +59.61% versus +4.93% for Healthcare, but that long-window advantage cannot repair the broken short-term hold; the event case remains context while follow-through is unresolved.

Session 6 · Aug 28, 2026 · 10:42 NASDAQGS
💬$68.47+0.87% base-3.27% prior

TEM’s tracked result fell 3.47 points to +1.04% as the early capture declined 3.14%, moved 1.15% below VWAP and held only 0.21x average volume. The event-driven thesis remains intact as context, but the price hold and participation condition that supported the repair have failed again.

Session 5 · Aug 27, 2026 · 15:51 NASDAQGS
💬$70.45+3.79% base+1.59% prior

TEM's tracked result improved 1.38 points to +3.95%, and the current capture is up 2.88% at 70.45, 0.36% above VWAP. The event-driven case still has price support, but volume is only 0.78 times average, participation is decelerating and the move remains 2.28 ATR above its reference; this is a held repair, not confirmed follow-through.

Session 3 · Aug 25, 2026 · 15:51 NASDAQGS
💬$68.55+0.99% base+0.21% prior

TEM tracked result improved 0.46 points to +0.90% as the stock gained 3.6% and held 0.29% above the session average, but participation was 1.08 times its three-month average and the move remains 2.3 ATR above its reference. Healthcare strength and accumulation keep the event-driven thesis alive; this is repair, not confirmation, until demand holds above the average price.

Session 2 · Aug 24, 2026 · 16:28 NASDAQGS
💬Aftermarket update: $66.15 (-0.03% vs regular close) · Aug 24, 2026 · 16:04 NASDAQGS$66.17-2.52% base-2.72% prior

TEM's tracked result fell 3.2 points to -2.17% after the current capture dropped 8.97% on 1.55x volume and finished 2.73% below VWAP near the bottom of its range. Healthcare-relative strength and the event mechanism remain visible, but continuation has lost its price hold again; the catalyst survives while the follow-through case remains unresolved.

Session 2 · Aug 24, 2026 · 10:36 NASDAQGS
💬$68.02+0.20% base-6.89% prior

TEM tracked result fell 5.93 points since the last panel note to +1.03%. The current capture dropped 6.43% on 0.49x volume and finished 2.04% below the session average near the lower range; strong healthcare-relative performance keeps the event explanation visible, but continuation has lost its price hold.

Session 1 · Aug 21, 2026 · 15:37 NASDAQGS
💬$71.93+5.96% base+5.87% prior

TEM tracked result improved 6.04 points to +6.96%, with price 2.33% above the session average and participation still at 2.07x. The event-driven continuation thesis remains supported by the structure and strong healthcare outperformance, but RSI at 82.03 and decelerating participation make that support conditional rather than confirmed.

Session 0 · Aug 20, 2026 · 14:15 NASDAQGS
Original publication💬$67.88 · +10.82% change on day

Panel thesis: TEM can continue its event-driven repricing while price holds VWAP and participation remains constructive. Invalidation boundary: A decisive loss of VWAP with fading participation invalidates the continuation thesis.

Panel comparison

Panel comparison

Selected candidate versus the alternatives retained from the panel comparison.

Latest display-only snapshot · Sep 11, 2026 · 18:17 NASDAQGS

TEMTempus AI, Inc.
Selected
$66.27

Since base -2.03% · Today -0.57% · Since prior +13.19% · Relative volume 1.83 · RSI 80.73 · EMA 56.01 > 52.93 > 51.57 · 52-week high 64.45% · As of Aug 20, 2026 · 17:20 NASDAQGS

ANDGAndersen Group Inc.
Alternative
$50.00

Since base +2.97% · Today -0.64% · Since prior 0.00% · Relative volume 4.72 · As of Aug 20, 2026 · 17:01 NASDAQGS

PURRHyperliquid Strategies Inc.
Alternative
$10.19

Since base +0.84% · Today +1.09% · Since prior 0.00% · Relative volume 1.66 · As of Aug 20, 2026 · 17:20 NASDAQGS

DEDeere & Company
Alternative
$620.85

Since base -1.71% · Today -0.01% · Since prior 0.00% · Relative volume 1.68 · As of Aug 20, 2026 · 17:19 NASDAQGS

Company dossier

History, curiosities & sources

Selected facts and links behind the public profile.

Company description

Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.